The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with prostate cancer was developed by the Society for Immunotherapy of Cancer (SITC) and published online by the Journal for ImmunoTherapy of Cancer, in 2016.Several new agents, including the immunotherapy drug sipuleucel-T, have been approved or are currently being investigated for the management of advanced prostate cancer. This consensus statement provides expert evidence-based recommendations for the use of immunotherapy and includes recommendations for patient selection, toxicity management, clinical end points and sequencing or combination of therapies.
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma."
Key points from SITC's Cancer Immunotherapy Guidelines Prostate Carcinoma have been distilled into Pocket Guide. This condensed, easily accessible version of the full Cancer Immunotherapy Guideline is a quick-reference tool available in both digital and print.Download SITC's Cancer Immunotherapy Guidelines Prostate Carcinoma Pocket Guide on any desktop or mobile device free today.*
*Available only through the Guideline Central App.
ORDER Digital/Print Guide
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org